These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25397630)

  • 1. [Nuclear Medicine in diagnosis of breast cancer].
    Iakovou IP; Giannoula E
    Hell J Nucl Med; 2014; 17(3):221-7. PubMed ID: 25397630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
    Buscombe JR; Holloway B; Roche N; Bombardieri E
    Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
    Avril N; Adler LP
    Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging of breast cancer.
    Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
    Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.
    Champion L; Brain E; Giraudet AL; Le Stanc E; Wartski M; Edeline V; Madar O; Bellet D; Pecking A; Alberini JL
    Cancer; 2011 Apr; 117(8):1621-9. PubMed ID: 21472709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
    de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
    Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of FDG-PET/CT in suspected recurrence of breast cancer.
    Radan L; Ben-Haim S; Bar-Shalom R; Guralnik L; Israel O
    Cancer; 2006 Dec; 107(11):2545-51. PubMed ID: 17063499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple (18)F-FDG, PET-CT for postoperative monitoring of breast cancer patients.
    Kurata A; Murata Y; Kubota K; Osanai T; Shibuya H
    Acta Radiol; 2009 Nov; 50(9):979-83. PubMed ID: 19863406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the diagnostic methods on the therapeutic strategies.
    Greco M; Agresti R; Giovanazzi R
    Q J Nucl Med; 1998 Mar; 42(1):66-80. PubMed ID: 9646647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG.
    Murthy K; Aznar M; Thompson CJ; Loutfi A; Lisbona R; Gagnon JH
    J Nucl Med; 2000 Nov; 41(11):1851-8. PubMed ID: 11079494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.